Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Spalt-like transcription factor 1 is a member of the SALL family of zinc finger transcription factors, distinct for its DNA-binding specificity toward A/T-rich sequences via C-terminal and double zinc finger domains. It localizes to heterochromatin, orchestrates gene repression, and is required for normal development, particularly of the kidney and other organs. Mutations in SALL1 cause Townes-Brocks syndrome, manifesting as multisystem developmental defects. SALL1 is implicated in chromatin remodeling, likely through interactions with the NuRD histone deacetylase complex, and regulates STEM cell and microglia identity by fine-tuning chromatin accessibility and transcriptional programs.
No approved drugs or tool compounds directly targeting SALL1. Mechanistic studies focus on loss- or gain-of-function interventions in model systems for disease modeling or cellular identity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Spalt-like transcription factor 1 (SALL1).